Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24 Late-Breaking Discussion: The ZODIAC Trial
Author(s): Harriette Van Spall , Kausik Ray Added: 12 months ago
AHA Conference 2024 — Key findings from the ZODIAC trial investigating the role of a decision support system in optimising lipid-lowering therapy for ACS patients.Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Kausik Ray (Imperial College London, UK) to discuss the findings from the randomized controlled ZODIAC trial assessing decision support systems (DSS) in optimising… View more

Prevention & Chronic Conditions

MI/ACS
AHA 23: SUPER LIPID
Author(s): Alexander Fanaroff Added: 2 years ago
AHA 2023 — We are joined by Dr Alexander Fanaroff (Penn Medicine, US) to discuss the findings from a cluster randomised trial of automated referral to centralised pharmacy services for evidence-based statin initiation in high-risk patients.Gaps have been observed in evidence-based statin prescriptions, where more than 50% of US adults with an indication for atherosclerotic cardiovascular disease… View more

Prevention & Chronic Conditions
Author(s): Evan A Stein Added: 1 year ago
ACC.24 — We are joined onsite by investigator, Dr Evan A Stein (Medpace Reference Laboratories, US) to discuss the findings from the LIBerate-CVD trial (NCT04797247).LIBerate-CVD investigated LDL-C reductions in a cohort of 900 patients with cardiovascular diseases and hyper-LDL-cholesterol treated with 300mg subcutaneous Lerodalcibep as compared to placebo across a 52-week treatment period… View more

Prevention & Chronic Conditions
New Horizons in Dyslipidaemia
Author(s): Peter Libby , Kausik Ray , Erik Stroes Start date: Feb 12, 2026
Join us forNew Horizons in Dyslipidaemia, a new one-day virtual educational event, taking place on 12 February 2026, designed for healthcare professionals involved in the management of cardiovascular risk and other lipid-related health conditions.This event will explore the rapidly evolving landscape of lipid management, addressing persistent gaps between perceived and actual cardiovascular risk… View more

Prevention & Chronic Conditions
Erik Stroes
Research Area(s) / Expertise: Job title: Chairman of the lipid clinic
Prof Erik Stroes is Chairman of the lipid clinic at Amsterdam University Medical Center (UMC) in the Netherlands. Prof Stroes is a vascular internist with a longstanding track of research in the field of lipidology, inflammation and atherosclerosis. His current research foci encompass the use of CT-angiography as a guide to tailored treatment regimens, pathophysiology of Lp(a) in atherogenesis… View more
AHA 25: CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3
Author(s): Stephen Nicholls Added: 1 week ago
AHA 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses targeting… View more

Prevention & Chronic Conditions
AHA 25 Late-breaking Discussion: The VESALIUS-CV Trial
Author(s): Erin A Bohula , Harriette Van Spall Added: 1 day ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9… View more

Heart Failure

Prevention & Chronic Conditions
Job title: Associate Professor of Medicine
Frederick Raal
Research Area(s) / Expertise: Job title: Professor and Director of the Carbohydrate and Lipid Metabolism Research Unit
Professor Frederick Raal is a distinguished Professor and the Director of the Carbohydrate and Lipid Metabolism Research Unit at the University of the Witwatersrand in Johannesburg, South Africa. He also serves as the Head of the Division of Endocrinology and Metabolism at the same institution.He graduated with an MBBCh degree in 1981, followed by a Master of Medicine in 1991, a PhD in 2000, and… View more
AHA 25: The CORALreef HeFH Trial
Author(s): Christie Ballantyne Added: 6 days ago
AHA Scientific Sessions 2025 - Dr Christie Ballantyne (Baylor College of Medicine, Houston, TX, US) discusses findings from the CORALreef HeFH trial, examining the efficacy and safety of enlicitide decanoate, an oral PCSK9 inhibitor, in adults with heterozygous familial hypercholesterolemia.This Phase 3, randomized, double-blind, placebo-controlled study evaluated 303 participants with… View more

Cardiovascular Renal Metabolic